caa a22 4500 475824520 CHVBK 20180406123827.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1023/A:1026543107533 doi (NATIONALLICENCE)springer-10.1023/A:1026543107533 The TETAMI Trial: The Safety and Efficacy of Subcutaneous Enoxaparin versus Intravenous Unfractionated Heparin and of Tirofiban versus Placebo in the Treatment of Acute Myocardial Infarction for Patients Not Thrombolyzed: Methods and Design [Elektronische Daten] [Marc Cohen, Frans Maritz, Gian Gensini, Nicolas Danchin, Ari Timerman, Kurt Huber, Enrique Gurfinkel, Harvey White, Keith Fox, Luc Vittori, Veronique Le-Louer, Frederique Bigonzi] Patients with acute myocardial infarction (AMI) who do not receive early reperfusion therapy are at high risk of reinfarction or death, and the efficacy and safety of antithrombotic therapy in this group of patients has not been evaluated. Enoxaparin is a low-molecular-weight heparin (LMWH) that has previously been shown to reduce the incidence of ischemic events in patients with unstable angina or non-Q-wave MI. The principal aims of the TETAMI study are to investigate the efficacy and safety of treatment with enoxaparin or tirofiban (a glycoprotein IIb/IIIa receptor antagonist) alone or in combination for 2 to 8 days in patients with AMI who are not eligible for early reperfusion therapy. In this 2 by 2 factorial design study approximately 900 patients will be randomly assigned, in a blinded manner, to one of four treatments: enoxaparin alone, enoxaparin plus tirofiban, unfractionated heparin (UFH), or UFH plus tirofiban, with appropriate matched placebos. The primary end point is the composite of death, recurrent AMI, and recurrent angina, analyzed at 30 days after AMI. The design and methods of the TETAMI study are described in this article. Kluwer Academic Publishers, 2000 acute myocardial infarction nationallicence antithrombotic treatment nationallicence enoxaparin nationallicence tirofiban nationallicence Cohen Marc Hahnemann University Hospital, Philadelphia, Pennsylvania, USA aut Maritz Frans Karl Bremer Hospital, Bellville, South Africa aut Gensini Gian Clinica Medica Generale e Cardiologia, Florence, Italy aut Danchin Nicolas Brabois Vandoeuvre, France aut Timerman Ari Dante Pazzanese, Sao Paulo, Brazil aut Huber Kurt University of Vienna, Vienna, Austria aut Gurfinkel Enrique Fundacion Favaloru, Buenos Aires, Argentina aut White Harvey Green Lane Hospital, Auckland, New Zealand aut Fox Keith The Royal Infirmary of Edinburgh, Edinburgh, United Kingdom aut Vittori Luc Aventis Pharma, Paris, France aut Le-Louer Veronique Aventis Pharma, Paris, France aut Bigonzi Frederique Aventis Pharma, Paris, France aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/3(2000-12-01), 241-246 0929-5305 10:3<241 2000 10 11239 https://doi.org/10.1023/A:1026543107533 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1026543107533 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Cohen Marc Hahnemann University Hospital, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 700 1- Maritz Frans Karl Bremer Hospital, Bellville, South Africa aut NATIONALLICENCE 700 1- Gensini Gian Clinica Medica Generale e Cardiologia, Florence, Italy aut NATIONALLICENCE 700 1- Danchin Nicolas Brabois Vandoeuvre, France aut NATIONALLICENCE 700 1- Timerman Ari Dante Pazzanese, Sao Paulo, Brazil aut NATIONALLICENCE 700 1- Huber Kurt University of Vienna, Vienna, Austria aut NATIONALLICENCE 700 1- Gurfinkel Enrique Fundacion Favaloru, Buenos Aires, Argentina aut NATIONALLICENCE 700 1- White Harvey Green Lane Hospital, Auckland, New Zealand aut NATIONALLICENCE 700 1- Fox Keith The Royal Infirmary of Edinburgh, Edinburgh, United Kingdom aut NATIONALLICENCE 700 1- Vittori Luc Aventis Pharma, Paris, France aut NATIONALLICENCE 700 1- Le-Louer Veronique Aventis Pharma, Paris, France aut NATIONALLICENCE 700 1- Bigonzi Frederique Aventis Pharma, Paris, France aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/3(2000-12-01), 241-246 0929-5305 10:3<241 2000 10 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer